Lv62
2060 积分 2025-02-25 加入
Sintilimab (PD-1 inhibitor) plus lenvatinib as conversion therapy followed by sequential surgery (SILENSES) for advanced unresectable hepatocellular carcinoma: a phase II, expansion trial
1个月前
已完结
Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study
2个月前
已完结
抗肿瘤药物引起手足综合征的机制及防治措施
5个月前
已完结
Forward and reverse cardio-oncology
5个月前
已完结
Pharmacokinetic exposure and treatment outcomes of lenvatinib in patients with renal cell carcinoma and differentiated thyroid carcinoma
6个月前
已完结
A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
6个月前
已完结
The benefit of conversion therapy for patients with unresectable hepatocellular carcinoma receiving atezolizumab plus bevacizumab using newly established oncological resectability criteria in Japan
8个月前
已完结
Vulnerable or High-Risk Plaque
1年前
已完结
皖公网安备34019202002308
